Ken Paulus of Prime Therapeutics becomes chairman of PCMA Board of Directors

Paulus honored to take on this role within our industry at this important time

September 15, 2020

Washington, D.C. — Today, the Pharmaceutical Care Management Association (PCMA) announced Ken Paulus, President and CEO of Prime Therapeutics, as its new chairman of the Board.

“I’m honored to take on this role within our industry at this important time,” said Mr. Paulus. “As we continue to deal with a crippling global pandemic, prescription drug access and affordability are central issues. We need to remain committed to putting patients first as we move forward.”

PCMA is the national association representing America’s pharmacy benefit managers (PBMs) which administer prescription drug plans for more than 266 million Americans with health coverage through Fortune 500 companies, health insurers, labor unions, Medicare, Medicaid, and the Federal Employees Health Benefits Program, as well as the Exchanges established by the Affordable Care Act.

“I’d like to thank Alan Lotvin for his leadership and dedication as PCMA’s chairman. He has navigated the association and the industry through a difficult time for our nation. I congratulate Ken on his new role,” said PCMA President & CEO JC Scott. “Our industry will benefit greatly from the diverse experience and expertise that he brings as the next chairman of PCMA.”

Related news

Press releases

October 19, 2021

Going beyond the first fill: Prime Therapeutics, NCODA collaboration enables improved patient outcomes through new oncology pharmacy accreditation

EAGAN, Minn. and CAZENOVIA, NY –  Prime Therapeutics (Prime), a leading pharmacy benefit…

Press releases

October 18, 2021

Cancer patients, caregivers benefit with integrated clinic-to-pharmacy care through Prime Therapeutics’ IntegratedRx™ – Oncology

EAGAN, Minn. – Prime Therapeutics, a leading pharmacy benefit manager (PBM) serving more…

Press releases

October 14, 2021

In first of its kind study, Prime Therapeutics explores paroxysmal nocturnal hemoglobinuria (PNH) C5 inhibitor treatment rates

EAGAN, Minn. – Leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) used its…